[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639444":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":12,"locations":10,"responsibleParty":18,"collaborators":10,"id":21,"slug":22,"hasResults":23,"nctId":24,"briefTitle":25,"officialTitle":25,"acronym":10,"eligibilityCriteria":26,"healthyVolunteers":23,"sex":27,"minAge":28,"maxAge":10,"enrollmentInfo":29,"targetDuration":32,"studyType":33,"phases":10,"briefSummary":34,"conditions":35,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":10},{"fullName":5,"class":6},"The Third Affiliated hospital of Zhejiang Chinese Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"Adults post-coronary revascularization.",null,"Patients aged ≥18 years who underwent coronary revascularization (PCI or CABG). Consecutive enrollment from 5 Chinese hospitals. Prospective follow-up at 12, 24, 36, and 48 weeks post-enrollment. Assessments include MACE (all-cause death, stent thrombosis, myocardial infarction, unstable angina, repeat revascularization, rehospitalization), TCM syndrome score, NYHA class, echocardiography, ambulatory ECG, and biospecimens (blood and tongue coating for proteomics, metabolomics, microbiomics). No intervention is assigned.",[13],{"name":14,"role":15,"phone":16,"phoneExt":10,"email":17},"Liu Qiang","CONTACT","13588121905","19981011@zcmu.com",{"type":19,"investigatorFullName":14,"investigatorTitle":20,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Principal Investigator","100639444","establishment-of-disease-characteristics-and-a-chinese-medicine-prognosis-risk-model-based-on-a-large-scale-database-after-coronary-revascularization-100639444",false,"NCT07613060","Establishment of Disease Characteristics and a Chinese Medicine Prognosis Risk Model Based on a Large-Scale Database After Coronary Revascularization","Inclusion Criteria:\n\n* Diagnosis of coronary artery disease with prior coronary revascularization (PCI or CABG)\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Malignant arrhythmias, severe heart failure, myocardial disease, or structural heart disease\n* Severe pulmonary insufficiency, severe liver or kidney dysfunction, severe electrolyte disturbances\n* Pregnancy or breastfeeding\n* Severe psychiatric disorders, malignant tumors, hematologic diseases, rheumatic immune diseases, or severe infection\n* Poor compliance or any other reason making the participant unsuitable for the study","ALL","18 Years",{"count":30,"type":31},600,"ESTIMATED","12 Months","OBSERVATIONAL","This study aims to develop a risk prediction model for patients who have undergone coronary revascularization (such as stent placement or bypass surgery). After these procedures, some patients still experience heart-related problems like chest pain, heart attack, or rehospitalization. This study will enroll 600 patients from multiple hospitals in China and follow them for 12 months. At enrollment and at 12, 24, 36, and 48 weeks after surgery, researchers will collect clinical information (including traditional Chinese medicine symptoms, blood tests, heart imaging) and biological samples (blood and tongue coating). Using artificial intelligence, the study will build a predictive model that combines Western medical data with traditional Chinese medicine characteristics. The goal is to better identify patients at higher risk of future heart events, so that personalized prevention and management can be provided. The study does not involve any experimental treatment or intervention - it is purely observational.",[36,37,38],"Coronary Artery Disease","Postoperative Period","Myocardial Revascularization","NOT_YET_RECRUITING","2026-05-21",{"date":42,"type":43},"2026-05-29","ACTUAL",{"date":45,"type":31},"2026-07-01",{"date":47,"type":31},"2028-12-31",{"name":14,"class":6}]